Rhumbline Advisers Innoviva, Inc. Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q3 2024

A detailed history of Rhumbline Advisers transactions in Innoviva, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 183,387 shares of INVA stock, worth $3.26 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
183,387
Previous 204,782 10.45%
Holding current value
$3.26 Million
Previous $3.36 Million 5.39%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$16.33 - $20.04 $349,380 - $428,755
-21,395 Reduced 10.45%
183,387 $3.54 Million
Q2 2024

Aug 01, 2024
SELL
$14.4 - $16.4 $47,880 - $54,529
-3,325 Reduced 1.6%
204,782 $3.36 Million
Q1 2024

May 09, 2024
SELL
$14.56 - $16.78 $6,246 - $7,198
-429 Reduced 0.21%
208,107 $3.17 Million
Q4 2023

Feb 08, 2024
BUY
$12.32 - $16.27 $39,941 - $52,747
3,242 Added 1.58%
208,536 $3.34 Million
Q3 2023

Nov 09, 2023
SELL
$12.37 - $13.89 $26,644 - $29,919
-2,154 Reduced 1.04%
205,294 $2.67 Million
Q2 2023

Aug 08, 2023
BUY
$11.39 - $13.72 $122,066 - $147,037
10,717 Added 5.45%
207,448 $2.64 Million
Q1 2023

May 11, 2023
BUY
$10.73 - $13.6 $114,489 - $145,112
10,670 Added 5.73%
196,731 $2.21 Million
Q4 2022

Feb 14, 2023
BUY
$11.8 - $13.78 $29,039 - $33,912
2,461 Added 1.34%
186,061 $2.47 Million
Q3 2022

Nov 10, 2022
BUY
$11.61 - $15.22 $43,734 - $57,333
3,767 Added 2.09%
183,600 $2.13 Million
Q2 2022

Aug 11, 2022
BUY
$14.32 - $19.88 $244,084 - $338,854
17,045 Added 10.47%
179,833 $2.65 Million
Q1 2022

May 12, 2022
SELL
$15.39 - $20.25 $254,412 - $334,752
-16,531 Reduced 9.22%
162,788 $3.15 Million
Q4 2021

Feb 10, 2022
SELL
$15.91 - $18.72 $92,468 - $108,800
-5,812 Reduced 3.14%
179,319 $3.09 Million
Q3 2021

Nov 12, 2021
SELL
$13.06 - $17.24 $552,124 - $728,838
-42,276 Reduced 18.59%
185,131 $3.09 Million
Q2 2021

Aug 05, 2021
BUY
$11.45 - $13.96 $145,941 - $177,934
12,746 Added 5.94%
227,407 $3.05 Million
Q1 2021

May 06, 2021
BUY
$11.06 - $12.87 $120,565 - $140,295
10,901 Added 5.35%
214,661 $2.57 Million
Q4 2020

Feb 10, 2021
BUY
$9.33 - $12.48 $96,845 - $129,542
10,380 Added 5.37%
203,760 $2.53 Million
Q3 2020

Nov 12, 2020
SELL
$10.33 - $14.49 $211,971 - $297,334
-20,520 Reduced 9.59%
193,380 $2.02 Million
Q2 2020

Aug 13, 2020
SELL
$11.49 - $15.26 $70,387 - $93,482
-6,126 Reduced 2.78%
213,900 $2.99 Million
Q1 2020

May 06, 2020
BUY
$8.11 - $15.23 $37,500 - $70,423
4,624 Added 2.15%
220,026 $2.59 Million
Q4 2019

Feb 05, 2020
BUY
$10.28 - $14.38 $97,958 - $137,027
9,529 Added 4.63%
215,402 $3.05 Million
Q3 2019

Oct 23, 2019
BUY
$10.05 - $14.55 $35,647 - $51,608
3,547 Added 1.75%
205,873 $2.17 Million
Q2 2019

Aug 14, 2019
BUY
$13.1 - $14.95 $45,234 - $51,622
3,453 Added 1.74%
202,326 $2.95 Million
Q1 2019

May 01, 2019
BUY
$13.69 - $20.06 $22,342 - $32,737
1,632 Added 0.83%
198,873 $2.79 Million
Q4 2018

Jan 31, 2019
BUY
$13.96 - $18.26 $444,137 - $580,941
31,815 Added 19.23%
197,241 $3.44 Million
Q3 2018

Nov 07, 2018
SELL
$13.63 - $15.7 $69,949 - $80,572
-5,132 Reduced 3.01%
165,426 $2.52 Million
Q2 2018

Aug 06, 2018
SELL
$13.44 - $17.59 $14,488 - $18,962
-1,078 Reduced 0.63%
170,558 $2.35 Million
Q1 2018

May 02, 2018
BUY
$13.8 - $16.99 $1,807 - $2,225
131 Added 0.08%
171,636 $2.86 Million
Q4 2017

Feb 09, 2018
BUY
$11.73 - $14.75 $231,491 - $291,091
19,735 Added 13.0%
171,505 $2.43 Million
Q3 2017

Nov 06, 2017
BUY
$12.06 - $14.12 $1.83 Million - $2.14 Million
151,770
151,770 $2.14 Million

Others Institutions Holding INVA

# of Institutions
227
Shares Held
78.9M
Call Options Held
37.6K
Put Options Held
300
View Full List

About Innoviva, Inc.

INVA Quotes by TradingView
  • Ticker INVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 69,706,000
  • Market Cap $1.24B
  • Description
  • Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...
More about INVA
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email